Benzinga · Mar 4, 2026
PL
NASDAQ · PLSE
Pulse Biosciences, Inc.
Healthcare · Medical - Instruments & Supplies
$55.20
Up+$0.99 (+1.83%)
Updated Sep 16, 2026, 11:12 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 933.16M
- P/E ratio
- -13.62
- Dividend yield
- 0.00%
- 52-week range
- $12.56 – $58.90
- Volume
- 472.34K
- Avg. volume
- 185.65K
Price performance
PLSE price history
1M range · 20 trading sessions · Daily adjusted prices
PLSE closed at $55.20 after 20 trading sessions, up 20.00% for the selected period.
- Last close
- $55.20
- Period change
- +20.00%
- Period low
- $46.00
- Period high
- $55.20
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $54.415 | $56.61 | $53.51 | $55.20 | 472.34K |
| Sep 14, 2026 | $52.30 | $55.78 | $51.60 | $54.21 | 505.83K |
| Sep 11, 2026 | $54.50 | $56.6099 | $50.315 | $53.11 | 664.33K |
| Sep 10, 2026 | $52.18 | $57.94 | $51.30 | $54.43 | 915.48K |
| Sep 9, 2026 | $49.76 | $58.90 | $48.4257 | $52.97 | 1.56M |
| Sep 8, 2026 | $52.93 | $53.105 | $47.70 | $48.79 | 769.58K |
| Sep 4, 2026 | $53.68 | $54.75 | $52.75 | $53.24 | 515.42K |
| Sep 3, 2026 | $53.79 | $55.37 | $53.11 | $54.71 | 706.62K |
| Sep 2, 2026 | $52.14 | $53.57 | $51.45 | $52.68 | 979.94K |
| Sep 1, 2026 | $49.93 | $54.3898 | $49.16 | $52.09 | 1.13M |
| Aug 31, 2026 | $48.02 | $50.61 | $47.57 | $50.33 | 657.95K |
| Aug 28, 2026 | $48.06 | $49.00 | $47.01 | $47.57 | 266.19K |
| Aug 27, 2026 | $47.73 | $49.95 | $47.55 | $48.56 | 260.28K |
| Aug 26, 2026 | $49.00 | $49.7399 | $47.925 | $48.10 | 270.31K |
| Aug 25, 2026 | $49.73 | $50.90 | $47.65 | $49.00 | 366.68K |
| Aug 24, 2026 | $50.34 | $50.34 | $46.34 | $49.13 | 345.89K |
| Aug 21, 2026 | $47.47 | $50.71 | $47.47 | $50.42 | 453.13K |
| Aug 20, 2026 | $46.76 | $48.5763 | $46.64 | $47.85 | 238.62K |
| Aug 19, 2026 | $46.07 | $48.84 | $46.07 | $47.02 | 420.89K |
| Aug 18, 2026 | $46.80 | $48.10 | $45.88 | $46.00 | 526.02K |
Latest PLSE news
The latest Smart Investors Daily articles mentioning PLSE.
Stock researchCompany · Overview
PLSE research
Overview
Company profile and research snapshot.
Company profile
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Freedom Capital Markets | Buy | — |
| Aug 17, 2026 | Needham | Buy | — |
| Aug 10, 2026 | Canaccord Genuity | Buy | — |
| Jun 4, 2026 | Canaccord Genuity | Buy | — |
| Jul 7, 2025 | Oppenheimer | Outperform | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Feb 20, 2026
Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript
ChartMill · Feb 19, 2026
Pulse Biosciences Inc (NASDAQ:PLSE) Narrows Q4 Loss, Beats Revenue Estimates
Pulse Biosciences narrows Q4 losses and beats revenue estimates, advancing key clinical trials for its bioelectric cardiac ablation technology.
Benzinga · Feb 19, 2026
Pulse Biosciences May Offer Up To $59.976M Common Shares
SEC.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
